Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) remains to be the only curative treatment for myelofibrosis (MF) but is associated with significant toxicity; it is therefore crucial to identify high-risk patients who might benefit from alternative therapies. In this issue of Blood, Hernández-Boluda et al. develop an improved machine-learning-based model and web-based application to predict high risk of allo-HCT for the treatment of MF.